Reports Q3 revenue $3.1M vs. $2.8M last year. “With our catalysts anticipated over the next 6 months in all of our core programs – including development of crofelemer for cancer therapy-related diarrhea, development of crofelemer for the rare/orphan indications of microvillus inclusion disease and short bowel syndrome with intestinal failure, and the ongoing U.S. commercial launch of Gelclair, the Company’s third prescription product – Jaguar’s board of directors has no intention of implementing a reverse split of the Company’s common stock,” said Lisa Conte, Jaguar’s president and CEO.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- JAGX Earnings this Week: How Will it Perform?
- Jaguar Health announces FDA approval of renewal of Canalevia-CA1
- Jaguar Health to present crofelemer results at SABCS
- Jaguar Health launches Gelclair prescription product in the U.S.
- Jaguar submits abstract for study of impact of diarrhea from cancer therapies